Sermonix Pharmaceuticals is dedicated to advancing women's oncology through the development of targeted therapies, particularly focusing on female-specific cancer treatments. The company is currently conducting the ELAINE Study, which is a multicenter, open-label trial aimed at evaluating the efficacy of lasofoxifene compared to fulvestrant in treating postmenopausal and premenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2-) breast cancer. This study specifically targets patients with an acquired estrogen receptor 1 (ESR1) mutation who have shown disease progression on aromatase inhibitors in combination with cyclin-dependent kinase (CDK) 4/6 inhibitors.

Lasofoxifene, the primary investigational drug being studied by Sermonix, has undergone extensive research for its potential in treating breast and ovarian cancers. The focus on this compound highlights the company's commitment to addressing the unique needs of women facing these diseases, particularly those with specific genetic mutations that may influence treatment outcomes. Through its clinical trials and ongoing research, Sermonix aims to provide innovative solutions that improve the quality of care and survival rates for women with cancer.

United States

Sermonix Pharmaceuticals, founded by David Portman, MD—a leading clinical researcher and expert in women’s health—focuses on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers.

Sermonix Pharmaceuticals

Company Details